| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,584,560 | 14 | 100 |
| BALL BRYAN | See remarks | 0 | $0 | 5 | $635,054 | $-635,054 |
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER | 0 | $0 | 3 | $890,613 | $-890,613 |
| Lennon David James | CHIEF EXECUTIVE OFFICER | 0 | $0 | 6 | $1.06M | $-1.06M |
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Over the last 12 months, insiders at Whitehawk Therapeutics Inc have bought $0 and sold $2.58M worth of Whitehawk Therapeutics Inc stock.
On average, over the past 5 years, insiders at Whitehawk Therapeutics Inc have bought $0 and sold $2.58M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-04-16 | Sale | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | 141,600 0.2929% | $4.13 | $584,808 | -3.31% | |
| 2026-04-15 | Sale | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | 77,000 0.1615% | $3.86 | $297,220 | +5.00% | |
| 2026-04-14 | Sale | BALL BRYAN | See remarks | 92,460 0.2009% | $3.64 | $336,554 | +2.25% | |
| 2026-04-13 | Sale | BALL BRYAN | See remarks | 26,389 0.0545% | $3.46 | $91,306 | +17.72% | |
| 2026-04-10 | Sale | BALL BRYAN | See remarks | 6,596 0.0135% | $3.43 | $22,624 | +20.35% | |
| 2026-04-09 | Sale | BALL BRYAN | See remarks | 50,000 0.1103% | $3.57 | $178,500 | +14.79% | |
| 2026-04-09 | Sale | Lennon David James | CHIEF EXECUTIVE OFFICER | 14,500 0.0303% | $3.38 | $49,010 | +14.79% | |
| 2026-04-08 | Sale | Lennon David James | CHIEF EXECUTIVE OFFICER | 63,945 0.1343% | $3.40 | $217,413 | +19.35% | |
| 2026-04-07 | Sale | Lennon David James | CHIEF EXECUTIVE OFFICER | 94,087 0.1994% | $3.43 | $322,718 | +18.66% | |
| 2026-04-06 | Sale | Lennon David James | CHIEF EXECUTIVE OFFICER | 102,395 0.2176% | $3.51 | $359,406 | +16.29% | |
| 2026-04-02 | Sale | Lennon David James | CHIEF EXECUTIVE OFFICER | 26,858 0.0559% | $3.48 | $93,466 | +15.95% | |
| 2026-03-02 | Sale | BALL BRYAN | See remarks | 1,834 0.0037% | $3.31 | $6,070 | +24.07% | |
| 2026-03-02 | Sale | Lennon David James | CHIEF EXECUTIVE OFFICER | 5,100 0.0102% | $3.31 | $16,879 | +24.07% | |
| 2026-03-02 | Sale | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | 2,594 0.0052% | $3.31 | $8,585 | +24.07% |
| Increased Positions | 22 | +50% | 5M | +16.12% |
| Decreased Positions | 12 | -27.27% | 503,019 | -1.74% |
| New Positions | 12 | New | 3M | New |
| Sold Out Positions | 6 | Sold Out | 423,627 | Sold Out |
| Total Postitions | 54 | +22.73% | 33M | +14.38% |